HER2+ Tumor Molecular Subtypes Predict Response to Dual HER2 Blockade [Clinical Trials]

Trastuzumab plus lapatinib achieves the highest response rates in HER2-enriched HER2⁺ breast tumors.

http://ift.tt/2plMaMv